<DOC>
	<DOCNO>NCT01149486</DOCNO>
	<brief_summary>The object study compare relative bioavailability ( rate extent absorption ) 100/25 mg Losartan potassium/Hydrochlorothiazide Tablets manufacture Teva Pharmaceutical Industries Ltd. distribute Teva Pharmaceuticals USA HyzaarÂ® 100/25 mg Tablets distribute Merck &amp; Co. , Inc. follow single oral dose ( 1 x 100/25 mg tablet ) healthy adult subject administer fasting condition .</brief_summary>
	<brief_title>Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets Healthy Subjects Under Fasting Conditions</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA Bioequivalence Statistical Methods</detailed_description>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Healthy men woman , 1845 year age ( inclusive ) . Body mass index less equal 30 Screening procedure complete within 28 day prior dose . If female : child bear potential , practice acceptable barrier method birth control duration study postmenopausal least 1 year surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) Subjects recent history drug alcohol abuse addiction . Subjects presence clinically significant disorder involve cardiovascular , respiratory , renal , gastrointestinal , immunologic , hematologic , endocrine , neurologic system ( ) psychiatric disease ( determined clinical investigator ) . Subjects whose clinical laboratory test value accept reference range confirm reexamination deem clinically significant . Subjects demonstrate positive hepatitis B surface antigen screen , positive hepatitis C antibody screen , reactive HIV antibody screen . Subjects demonstrate positive drug abuse screen screen study . Female subject demonstrate positive pregnancy screen . Female subject currently breastfeed . Subjects use implant injected hormonal contraceptive anytime 180 day prior study dose hormonal contraceptive within 14 day dose allowed participate . Subjects history allergic response ( ) losartan , hydrochlorothiazide related drug . Subjects history clinically significant allergy include drug allergy . Subjects clinically significant illness 4 week prior dose ( determined clinical investigator ) . Subjects take drug know induce inhibit hepatic drug metabolism 28 day prior dose . Subjects use tobacco product within 90 day Period 1 dose administration . Subjects report donate great 150 mL blood within 14 day prior dose . Subjects report receive investigational drug within 28 day prior dose . Subjects report take systemic prescription medication 14 day prior dose . Subjects report intolerance direct venipuncture . Subjects report consume abnormal diet within 28 day prior dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>